论文部分内容阅读
罗氏公司目前决定停止并收回钙拮抗剂Ｐｏｓｉｃｏｒ（ｍｉｂｅｆｒａｄｉｌ）在世界市场的销售，因该药在使用过程中在药物相互作用方面出现了问题。预计该药的销售额约为８亿瑞士法郎（６亿美元）。与此同时，罗氏公司公布了一个强项产品计划，即１９９９年将有下述８种...
Roche has now decided to stop and reclaim the sales of the calcium antagonist Posicor (mibefradil) in the world market as a result of its drug-drug interactions. The drug is estimated to have sales of about 800 million Swiss francs (600 million U.S. dollars). In the meantime, Roche announced a strong product program that will have the following eight in 1999 ...